Insmed’s DPP1 inhibitor has received FDA approval as the first treatment for chronic respiratory disease bronchiectasis. This milestone marks a significant step forward in managing lung diseases, offering new hope to patients affected by this condition.
Source: https://endpoints.news/insmed-gets-fda-approval-for-the-first-dpp1-inhibitor-in-lung-disease